Avicanna Inc

Avicanna's capital structure is characterized by a debt-to-equity ratio of 0.0, indicating no long-term debt, and a current ratio of 0.86, suggesting limited short-term liquidity. The company's operating cash flow is negative at -1.18 million CAD, and free cash flow is -2.27 million CAD, reflecting ongoing cash burn. These metrics indicate a liquidity risk, as the company is not generating positive cash flow from operations. Profitability metrics show a return on equity of -100.02% and a return on assets of -13.39%, both significantly below the industry median for biotechnology and medical research firms. The company reported a net loss of 2.84 million CAD and an operating loss of 2.78 million CAD, indicating a lack of profitability. Gross profit of 13.74 million CAD is a positive, but it is insufficient to offset operating expenses. The company's revenue is concentrated in a single business model, with no disclosed geographic diversification. The four main product categories—medical cannabis products, the MyMedi.ca platform, pharmaceutical pipeline, and active pharmaceutical ingredients—do not provide segment-level revenue breakdowns, making it difficult to assess diversification or growth drivers. The lack of geographic data also limits understanding of exposure to regional market risks. Growth trajectory is constrained by the company's current financial position. Revenue for the latest period is 25.48 million CAD, but no year-over-year growth data is provided. The outlook for the current fiscal year is not explicitly stated, but the negative operating and free cash flows suggest a challenging path to growth. The company's pipeline, including Trunerox, may offer long-term potential, but no near-term revenue impact is evident. Risk factors include a low liquidity score and the absence of long-term debt, which may limit the company's ability to fund operations or expansion. The risk assessment indicates no immediate filing-based liquidity or dilution flags, but the company's negative cash flows and low equity position suggest a high risk of needing to raise additional capital. No dilution sources are identified in the latest filings, but the company's financial position could necessitate future equity issuance. Recent events include the continued development of the Trunerox pipeline and the maintenance of the RHO Phyto brand. No recent filings or transcripts indicate significant changes in strategy or operations. The company's focus remains on advancing its medical cannabis and pharmaceutical products, but no material developments have been disclosed in the latest financial data.